CSS
IOVA icon

Cubist Systematic Strategies’s Iovance Biotherapeutics IOVA Stock Holding History

Cubist Systematic Strategies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,900
Closed -$562K – 3156
2024
Q4 		$562K Hold
75,900
– – ﹤0.01% 2129
2024
Q3 		$713K Sell
75,900
-28,400
-27% -$269K ﹤0.01% 2025
2024
Q2 		$836K Hold
104,300
– – 0.01% 1851
2024
Q1 		$1.55M Buy
+104,300
New +$1.21M 0.01% 1837

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Cubist Systematic Strategies's IOVA Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 468,821 shares — an estimated $5.46M sold.

Cubist Systematic Strategies first reported a position in IOVA in Q1 2015 and held it in 21 quarters. The position peaked at $7.9M in Q2 2020. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 468,821 Iovance Biotherapeutics shares in Q1 2024, an estimated $5.46M.
  • Cubist Systematic Strategies first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 21 quarters.
  • Cubist Systematic Strategies's Iovance Biotherapeutics position peaked at $7.9M in Q2 2020.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.